Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

Pfizer

Status and phase: Completed; Phase 2

Conditions: Urinary Bladder, Overactive

Treatments: Drug: Placebo; Drug: UK-369,003

Study type: Interventional

Funder types: Industry

Identifiers

NCT00479505

A3711047

Details and patient eligibility

About

This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

Enrollment: 275 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male subjects aged 18 years and above
• documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times / 24 hours and number of urgency episodes > 1 episode / 24 hours.

Exclusion criteria

• Neurological diseases known to affect bladder function.
• Urinary tract infection.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

275 participants in 2 patient groups, including a placebo group

Active

Experimental group

Treatment:

Drug: UK-369,003

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo